“700mg IV Leronlimab, administered at onset of immunologic dysfunction, likely will have nearly 100% mortality reduction.”

Highly unlikely that a a nearly 100% reduction in mortality is achieved, but I agree that with dose titration using advanced diagnostics, mortality could be reduced much more than the 30-40% in the S/C population. If the S/C trial is successful, CYDY should immediately modify the phase 4 protocol to include more than 2 doses and diagnostics to guide the improvement of efficacy.